Rhopressa is a ROCK-inhibitor, or Rho-associated coil–forming protein kinase inhibitor, approved by the FDA a few weeks ago.
Synapse Academy subscribers will already know from Volume 5, Issue 1, Glaucoma that it increases outflow through the trabecular meshwork and drops episcleral venous pressure.
It reduced IOP by 28% during trials and appears particularly good for patients who start treatment with lower pressures. Side effects are similar to the prostaglandin analogues: Hyperemia and tenderness. Also vortex keratopathy, pain on instillation
and conjunctival hemorrhage may occur.